Breaking News

GenScript Establishes Operations Site & Logistics Center in Sydney, Australia

Significantly enhances its ability to serve customers across the region.

GenScript Biotech Corporation, a leader in life sciences services and products, has established a new operations site and logistics center in Sydney, Australia.
 
The new Sydney facility will significantly enhance GenScript’s ability to serve customers across the region, ensuring faster and more efficient delivery of research reagents and products. With a local presence, Australian researchers and biotech companies will no longer need to navigate the complexities of permit applications, customs clearance, and tax payments, streamlining the procurement process, and allowing them to focus on advancing their groundbreaking research and innovation.
 
A key highlight of the Sydney site is the introduction of next-day shipping for high-demand products such as off-the-shelf mRNA, growth factors, Cas proteins, and more. This expedited service ensures that researchers and biotech companies can quickly access essential materials, accelerating their scientific discoveries and development efforts.
 
Sherry Shao, GenScript’s rotating CEO, commented: “Establishing a logistics hub in Sydney enables us to deliver more localized support to our Australian partners. We see this as more than just an operational expansion – it’s about building long-term relationships within the region’s biotech ecosystem. By removing import barriers and offering next-day delivery on key products, we are helping our customers focus entirely on advancing their research, without the logistical challenges that previously existed.”
 
Consistent with GenScript’s global effort, this new facility underscores GenScript’s mission to revolutionize the supply chain for Australian biotech companies, fostering a more dynamic and efficient research environment. By removing logistical barriers and offering next-day shipping for key products, GenScript aims to empower the biotechnology community to focus on innovation and discovery.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters